大鼠中枢内源性镇痛系统内GABAB受体的分布

目的：观察α－氨基丁酸B受体（GABAR）在大鼠中枢内源性镇痛系统内的定位分布,方法：GABABR特异性抗体的免疫组织化学染色方法：结果：GABABR样阳性胞体较密集地分布于中缝核簇的核团,如中缝背核,中缝正中核,中缝桥核,中缝大核,中缝苍白核,中缝隐核,此外,中脑导水管周围灰质和巨细胞网状核α部内也有GABAR样阳性胞体,上述核团内亦可见GABABR样阳性纤维和终末,结论：中枢内源性镇痛系统内有GABABR样阳性胞体,纤维及终末,这些阳性结构可能与对该系统的调控有关。     

穴位体表电刺激对术后PCEA的强化效应

目的　观察穴位体表电刺激对术后患者硬膜外自控镇痛（PCEA）效果、镇痛药用量、血清皮质醇浓度和不良反应的影响。方法　 选择经腹全宫切除术患者40例（ASAⅠ～Ⅱ级）,随机分成二组,每组20例。A组：于术后第4,8小时 Han's各刺激30 min,术后行PCEA。B组：单纯行术后PCEA（对照组）。术后随访镇痛效果、镇静评分、布氏舒适评分（BCS）,分段记录24 h镇痛药用量及总按压次数/实进次数（D1/D2）比值,血清皮质醇含量,肛门恢复排气时间和不良反应情况。结果　两组镇痛效果满意,A组BCS评分高于B组（P＜0.05）。A组镇痛药用量为（31.7±1.9）ml,与对照组（34.2±2.1）ml相比差异有显著性（P＜0.01）。血清皮质醇浓度两组均较术前下降,但A组术后8 h的下降幅度大于对照组。A组恢复肛门排气时间快于B组,而且恶心、呕吐与对照组相比有所减少。结论　术后患者硬膜外腔自控镇痛（PCEA）复合应用穴位体表电刺激,可增强镇痛效果,减少用药量,降低不良反应,是安全有效的复合镇痛方法。     

全麻诱导前预注芬太尼“先发镇痛”效应临床研究

目的：探讨全麻预注芬太尼的先发镇痛效应。／方法：选择40例择期全麻病人,随机分成试验组与对照组（n=20例）,术前常规用药,试验组诱导前用芬太尼5ug/kg,对照组将芬太尼改切皮后静注,术中麻醉维持相同,手术结束后病人自然清醒。术后有镇痛药使用意愿者均使用哌替啶镇痛。结果：两组病人一般情况及芬太尼总用量无显著性差异（P＞0．05）,试验组初次使用镇痛药时间明显延长（P＜0．01）,用药次数及剂量也显著少于对照组（P＜0．01）,试验组术后仅7（35％）例使用派替啶,而对照组使用哌替啶者达15（75％）例,两组差异性显著（P＜0．05）,结论：全麻前预注芬太尼具有良好的先发镇痛效应。     

关节灵片镇痛、抗炎作用的实验研究

为探讨关节灵片的镇痛、抗炎作用,用热板法和扭体法观察该药镇痛作用,结果关节灵片为不同剂量灌胃给药对小鼠热致痛和醋酸致痛均有明显抗痛作用,呈现一定的量效关系;关节灵片对二甲苯所致炎性水肿亦有显著的抑制作用。提示关节灵具有较好的镇痛抗炎作用。     

子宫峡部阻滞麻醉应用于人工流产术的临床观察

目的　探讨人工流产术中最佳的镇痛方法 ,方法　用带 7号针头的注射器 ,于宫颈 3点、9点距宫颈外口约 1cm处水平穿刺进针约 3cm ,回抽无血后 ,分别推注 2 %盐酸利多卡因各 3ml,2min后手术。结果　子宫峡部阻滞麻醉后 ,疼痛明显减轻或消失 ,与对照组相比有极显著性差异 (P <0 .0 1) ,人工流产综合征发生率明显低于对照组 (P <0 .0 1)。结论　子宫峡部阻滞麻醉开展无痛人流安全、简便、有效。     

小儿术后硬膜外持续输注吗啡的镇痛效果观察

目的 :探索小儿硬膜外持续输注吗啡术后镇痛的有效剂量及并发症。方法 :选择ASAI～Ⅱ级择期腹部、尿道及下肢手术行硬膜外复合全麻患儿32例 ,随机分为3组。术毕前60min于硬膜外腔注入30μg/kg吗啡 ,术后镇痛维持量分别为 :组1为1μg·kg-1·h-1 ,组2为1.5μg·kg-1·h-1,组3为2μg·kg-1·h-1。观察镇痛效果及不良反应。结果 :镇痛评分组2、3明显低于组1 ,组3恶心、呕吐、搔痒、呼吸抑制发生率明显高于组1、2。结论 :负荷量30μg/kg,维持量1.5μg·kg-1·h -1为小儿硬膜外持续输注吗啡的安全有效剂量     

分娩镇痛的临床观察

目的 探讨布比卡因硬膜外自控镇痛和罗湃卡因蛛风膜下腔－硬膜外自控镇痛用于分娩的效果及对产程、母婴的影响。方法 ９０例初产妇分为３组,布比卡因硬膜外自控镇痛组（Ａ组,ｎ＝３０）、罗哌卡因蛛网膜下腔－硬膜外自控镇痛组（Ｂ组,ｎ＝３０）和对照组（Ｃ组,ｎ＝３０,未行分娩镇痛）,观察各组镇痛效果、产程时间、分娩方式血清皮质醇及新生儿Ａｐｇａｒ评分情况。结果 Ａ,Ｂ组镇痛效果满意,以Ｂ组为佳两组 产程未血清     

Etodolac in the management of pain: A clinical review of a multipurpose analgesic

Etodolac is a non-steroidal anti-inflammatory drug with analgesic properties. Its primary anti-inflammatory mechanism of action is through a selective effect on cyclo-oxygenase-2 (COX-2). It is rapidly absorbed after oral administration, and maximum plasma concentration (C_max) is reached in 1-2 h, with an elimination half-life (t1/2 ) of 6-8 h. Etodolac has been widely applied in the treatment of inflammatory arthritides such as rheumatoid arthritis, ankylosing spondylitis and gout and in osteoarthritis and has been shown to be efficacious and well tolerated. However, etodolac has other applications which rely primarily on its efficacy as an analgesic. In particular, etodolac has been evaluated in the treatment of a variety of different pain states. Etodolac has been observed to be efficacious in the treatment of acute pain following dental extraction, orthopaedic and urological surgery, and episiotomy, as well as in the treatment of pain due to acute sports injuries, primary dysmenorrhoea, tendonitis, bursitis, periarthritis, radiculalgia and low back pain. These studies indicate that etodolac is a multipurpose analgesic with many clinical applications in addition to its use in the treatment of inflammatory and degenerative forms of arthritis.     

Oligogenic determination of morphine analgesic magnitude: A genetic analysis of selectively bred mouse lines

Two ongoing selective breeding projects have produced mice that display divergent analgesic responses to morphine. These two projects have selected for similar phenotypes: high and low levorphanol analgesia (HAR/LAR lines; Portland, OR) and high and low swim stress-induced analgesia (HA/LA lines; Jastrzebiec, Poland). Evidence suggests genetic commonalities between mice of the two projects. Using a Mendelian breeding protocol, we have recently found that one or two genetic loci predominantly determine the high morphine analgesia exhibited by HA mice. In the present study we demonstrate that the differential morphine analgesia (5 mg/kg. i.p.) displayed by HAR and LAR mice is similarly oligogenic, predominantly determined by two unlinked loci. A complementation analysis, in which the analgesic responses to morphine of the recessive homozygotes of each project (HAR and HA) were compared to those of their hybrid offspring (HAR x HA), revealed that different genetic loci have been fixed in each project. An intriguing bimodal distribution was observed in the HAR x HA population: Some HAR x HA hybrids displayed greater morphine analgesia than either HAR or HA mice, whereas others displayed minimal analgesia. LAR x LA hybrids displayed less analgesia than either LAR or LA mice. The analgesic responses of HAR x LA and LAR x HA mice were comparable to those of their low-line parents. These findings indicate not only that different loci were responsible for producing high morphine responders in each selection project but that these distinct loci can interact synergistically to produce superhigh and superlow responders.     

食管癌术后一次性硬膜外注射和肌肉注射镇痛法的比较

目的：确定硬膜外一次性镇痛法对食管癌病人术后的镇痛效果和减少并发症的意义。方法：９３ 例病人随机分成实验组（ Ｔ 组,５１ 例） 和对照组（ Ｃ 组,４２ 例） , Ｔ 组于手术结束缝合皮肤切口时经硬膜外导管于 Ｔ６ － ７ 水平注射吗啡１ ｍｇ 加１ ％ 普鲁卡因１０ ｍｌ, Ｃ 组用阿片类药物肌肉注射镇痛。结果： Ｔ 组病人术后疼痛明显减轻,各种并发症显著下降。结论：硬膜外一次性镇痛效果确切,操作方便,副作用少,对降低术后心肺并发症很有意义,尤其对年龄大、心肺功能差的病人较适合。